BioIVT says IDBS helped it deliver research data at least four weeks faster. The company’s bigger bet: better lab records can speed the journey from experiment to manufacturing - and give AI something trustworthy to work with.
The Cambridge company began with one postdoc’s bad antibody problem. Twenty-eight years later, its real product is not merely a vial - it is the confidence that a costly experiment will not have to be run twice.